Literature DB >> 17911348

Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling.

Eun-Gyoung Hong1, Dae Young Jung, Hwi Jin Ko, Zhiyou Zhang, Zhexi Ma, John Y Jun, Jae Hyeong Kim, Andrew D Sumner, Thomas C Vary, Thomas W Gardner, Sarah K Bronson, Jason K Kim.   

Abstract

Although insulin resistance has been traditionally associated with type 2 diabetes, recent evidence in humans and animal models indicates that insulin resistance may also develop in type 1 diabetes. A point mutation of insulin 2 gene in Ins2(Akita) mice leads to pancreatic beta-cell apoptosis and hyperglycemia, and these mice are commonly used to investigate type 1 diabetes and complications. Since insulin resistance plays an important role in diabetic complications, we performed hyperinsulinemic-euglycemic clamps in awake Ins2(Akita) and wild-type mice to measure insulin action and glucose metabolism in vivo. Nonobese Ins2(Akita) mice developed insulin resistance, as indicated by an approximately 80% reduction in glucose infusion rate during clamps. Insulin resistance was due to approximately 50% decreases in glucose uptake in skeletal muscle and brown adipose tissue as well as hepatic insulin action. Skeletal muscle insulin resistance was associated with a 40% reduction in total GLUT4 and a threefold increase in PKCepsilon levels in Ins2(Akita) mice. Chronic phloridzin treatment lowered systemic glucose levels and normalized muscle insulin action, GLUT4 and PKCepsilon levels in Ins2(Akita) mice, indicating that hyperglycemia plays a role in insulin resistance. Echocardiography showed significant cardiac remodeling with ventricular hypertrophy that was ameliorated following chronic phloridzin treatment in Ins2(Akita) mice. Overall, we report for the first time that nonobese, insulin-deficient Ins2(Akita) mice develop type 2 diabetes phenotypes including peripheral and hepatic insulin resistance and cardiac remodeling. Our findings provide important insights into the pathogenesis of metabolic abnormalities and complications affecting type 1 diabetes and lean type 2 diabetes subjects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17911348     DOI: 10.1152/ajpendo.00256.2007

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  31 in total

1.  Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis.

Authors:  Vaibhav B Patel; Sreedhar Bodiga; Ratnadeep Basu; Subhash K Das; Wang Wang; Zuocheng Wang; Jennifer Lo; Maria B Grant; JiuChang Zhong; Zamaneh Kassiri; Gavin Y Oudit
Journal:  Circ Res       Date:  2012-04-03       Impact factor: 17.367

2.  Endothelial cell-specific overexpression of endothelial nitric oxide synthase in Ins2Akita mice exacerbates diabetic nephropathy.

Authors:  Mohan Natarajan; Samy L Habib; Robert L Reddick; Caroline R Delma; Krishnan Manickam; Thomas J Prihoda; Sherry L Werner; Sumathy Mohan
Journal:  J Diabetes Complications       Date:  2018-10-13       Impact factor: 2.852

Review 3.  The Prevalence and Management of Diabetic Nephropathy in Asia.

Authors:  Yasuhiko Tomino; Tomohito Gohda
Journal:  Kidney Dis (Basel)       Date:  2015-04-30

4.  VMAT2 identified as a regulator of late-stage β-cell differentiation.

Authors:  Daisuke Sakano; Nobuaki Shiraki; Kazuhide Kikawa; Taiji Yamazoe; Masateru Kataoka; Kahoko Umeda; Kimi Araki; Di Mao; Shirou Matsumoto; Naomi Nakagata; Olov Andersson; Didier Stainier; Fumio Endo; Kazuhiko Kume; Motonari Uesugi; Shoen Kume
Journal:  Nat Chem Biol       Date:  2013-12-15       Impact factor: 15.040

5.  Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.

Authors:  Paras K Mishra; Neetu Tyagi; Utpal Sen; Irving G Joshua; Suresh C Tyagi
Journal:  Cardiovasc Diabetol       Date:  2010-09-09       Impact factor: 9.951

6.  Heterogeneous nuclear ribonucleoproteins F and K mediate insulin inhibition of renal angiotensinogen gene expression and prevention of hypertension and kidney injury in diabetic mice.

Authors:  S Abdo; C-S Lo; I Chenier; A Shamsuyarova; J G Filep; J R Ingelfinger; S-L Zhang; J S D Chan
Journal:  Diabetologia       Date:  2013-04-23       Impact factor: 10.122

Review 7.  Mechanisms of disease: using genetically altered mice to study concepts of type 2 diabetes.

Authors:  Derek Leroith; Domenico Accili
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-01-22

8.  Genetic ablation of lymphocytes and cytokine signaling in nonobese diabetic mice prevents diet-induced obesity and insulin resistance.

Authors:  Randall H Friedline; Hwi Jin Ko; Dae Young Jung; Yongjin Lee; Rita Bortell; Sezin Dagdeviren; Payal R Patel; Xiaodi Hu; Kunikazu Inashima; Caitlyn Kearns; Nicholas Tsitsilianos; Umber Shafiq; Leonard D Shultz; Ki Won Lee; Dale L Greiner; Jason K Kim
Journal:  FASEB J       Date:  2015-12-07       Impact factor: 5.191

9.  Genetic and Pharmacologic Models for Type 1 Diabetes.

Authors:  Edward H Leiter; Andrew Schile
Journal:  Curr Protoc Mouse Biol       Date:  2013-03-01

10.  Deficiency of phosphoinositide 3-kinase enhancer protects mice from diet-induced obesity and insulin resistance.

Authors:  Chi Bun Chan; Xia Liu; Dae Young Jung; John Y Jun; Hongbo R Luo; Jason K Kim; Keqiang Ye
Journal:  Diabetes       Date:  2010-01-12       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.